Hidrasec Za Dojenčke (Racecadotril)

Hidrasec Za Dojenčke is indicated for the symptomatic treatment of acute, non‑bloody diarrhea in infants and children.

• Reduces stool frequency and volume in mild to moderate diarrheal episodes.
• Helps maintain hydration by decreasing intestinal water loss.
• Can be used alongside oral rehydration solutions as part of standard care.
• May be considered when rapid symptom relief is desired in pediatric patients.
• Suitable for short‑term use, typically a few days, until diarrheal symptoms improve.
• Not intended for chronic diarrheal conditions or for use in infants with blood in stool.

• Racecadotril acts as an inhibitor of intestinal enkephalinase, the enzyme responsible for degrading endogenous enkephalins. By blocking this enzyme, the drug increases the local concentration of enkephalins, which bind to opioid receptors on the enteric nervous system. This interaction reduces the secretion of water and electrolytes into the intestinal lumen, thereby decreasing stool output without affecting intestinal motility.

Like many antidiarrheal agents, racecadotril may be associated with adverse reactions, although most are mild and transient.

Common

• Mild abdominal discomfort or cramps that usually resolve without intervention.
• Nausea or occasional vomiting, typically mild and transient.
• Transient headache, often described as mild pressure.
• Loose stools persisting beyond the treatment period, indicating possible inadequate response.

Serious

• Allergic reactions such as rash, itching, swelling of the face or lips, which may require medical attention.
• Severe abdominal pain or signs of intestinal obstruction, including bloating and inability to pass gas or stool.
• Signs of liver dysfunction, for example elevated liver enzymes detected on laboratory testing.

When using Hidrasec Za Dojenčke, certain precautions should be observed to ensure safe and appropriate use in pediatric patients.

• Verify that diarrhea is acute, non‑bloody, and not associated with fever or dehydration before starting treatment.
• Ensure the child is adequately hydrated; oral rehydration solutions should be given concurrently.
• Do not use in infants younger than the label‑specified age or without medical guidance.
• Discontinue the medication if stools contain blood, mucus, or if the condition persists beyond 48‑72 hours.
• Consult a healthcare professional if the child has known gastrointestinal or metabolic disorders.
• Avoid use in patients with a history of hypersensitivity to racecadotril or related compounds.

Racecadotril may interact with certain medications; awareness of these interactions helps maintain efficacy and safety.

Avoid

• Concomitant use with potent opioid agonists, which could diminish the drug’s antidiarrheal effect.
• Co‑administration with drugs that significantly alter intestinal motility, such as prokinetics, may counteract therapeutic goals.

Use with caution

• Antacids containing aluminum or magnesium may affect absorption; monitor clinical response.
• Use cautiously with other enkephalinase inhibitors or opioid‑related agents due to additive effects.
• In patients receiving diuretics, monitor electrolyte balance as reduced intestinal loss may influence systemic levels.
• If the child is on antibiotics for gastrointestinal infection, observe for any changes in diarrhea pattern.